Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Meet the Stars of the Feline World: Well known Pet Feline Varieties - 2New Jordan security fence could be done in early 2028
- 3Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test
- 4Vacuum Cleaners That Are Not difficult To Use For Home
- 5Investigating Design and Individual Style: Track down Your Remarkable Look
- Vote in favor of your Number one method for praising a birthday
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- FDA approves Wegovy pill for weight loss: What to know
- Why this Tennessee special election has the 'whole world' watching
- Shipping: The Corridors of Trade and the Coming of Another Period
- Palestinians tell BBC they were sexually abused in Israeli prisons
- Building a Flourishing Business: Illustrations from Business people
- The 1st full moon of 2026 rises tonight! Here's what to expect from January's supermoon Wolf Moon
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
